Blue Horseshoe Stocks: DAL Options Idea

Delta Airlines, Inc. DAL

To start things off this morning, we’re immediately drawn to the most recognizable name on the premarket earnings calendar for the day. Delta has been beaten back over the past few weeks, to the point of approaching heavily oversold territory, especially as the PPS fell below the 50DMA for the first time since the second week of February.  When that did occur, the stock launched into a month-long bullish pattern. All of this is plainly evident on the chart snapshot below.

With this morning’s beat on earnings as a catalyst, we’ll look for a similar pattern to emerge this time around, and begin tracking the DAL 04/13 51.50-53 Calls.


Extended Watchlist:
RESN, DCIX, CBI, MDR, CHFS, OSTK, RIOT, EYEG, AKER

Blue Horseshoe Stocks: More Options Success

SPDR S&P 500 ETF (SPY) – Options Recap
-
Our options calls we made for the SPY on Friday morning were very good to us, and were an excellent way to close out what was ultimately a very successful trading week.

We put a flag up on the SPY Weekly $274.50-277 Calls after seeing the markets stabilize last midweek, following a couple of turbulent sessions as a result of Trump administrations newly announced tariffs. Things looked ripe for a rebound on Friday and that’s just what we got, with the SPY turning in a bullish performance from start to finish.

There were six sets of contracts contained in our designated range, and regardless of which strike price was chosen, intraday gains were on the table, ranging from very good to absolutely fantastic.

$272 Calls – Range: 1.30-4.31 – Max Gain: 232%
$272.50 Calls – Range:  .80-3.90 – Max Gain: 387%
$273 Calls – Range: .68-3.25 – Max Gain: 378%
$273.50 Calls – Range: .46-2.90 – Max Gain: 530%
$273 Calls – Range: .26-2.45 – Max Gain: 842%
$273.50 Calls – Range: .10-1.90 – Max Gain: 1800%

_______

Burlington Stores, Inc. BURL – Speaking of multi-bag options winners, we slated the  BURL 03/16 $120 & $125 Calls for observation on Thursday morning, and those finished out the week with stregth as well. The $120 Calls ran from 4.04-8.50, for an intraday rip of 110%, while the $125 nearly doubled that performance with a 212% run from 1.35-4.21.


Lumentum Holdings, Inc. LITE

We want to swing back around to recap the recent performance of LITE as well. Since our alert on the stock on February 7th, at which time the stock was trading for as little as 52.20/share, LITE has made considerable and steady upward progress.

On Friday it hit a new high of 69.25, marking a move of 33% in less than five weeks. That is quite a feat for a stock that started out above $50!

_______________

Fresh Options Idea:

Valeant Pharma International, Inc. VRX -We’re going to formulate a short and longer-term options idea for VRX, which is looking like it could be ready for a bottom bounce. Last week, an insider buy to the tune of more than $108.8M came in as well, which just reinforces our assumption that for now the stock has gone as low as it’s going to go.

We’ll be looking at the VRX Weekly $15 & $15.50 Calls, as well as the 04/13 $16 & $16.50 Calls.


Extended Watchlist:
ADMS, AKER, CPST, KANG, MRTX, NPTN, ENRJ

Blue Horseshoe Stocks: Ford Options Recap & More

Ford Motor Co. F

Back on February 12th, we flagged Ford as a bottom watch play after the company got off to a bad start in 2018. It had just begun to show signs of life, so we formulated an options idea to help us take advantage of the scenario.

Our targets were the F 03/02 10.37-11.37 Calls and we’ve seen some solid opportunities from three of the four contracts in that range in the two weeks since our alert.

$10.37 Calls – Range: .31-.55 – Max Gain: 77%
$10.87 Calls – Range: .04-.12 – Max Gain: 200%
$11 Calls – Range:.02-.07 – Max Gain: 250%


Target Corp. TGT

Yesterday morning we saw an opportunity to select a range of calls in the Target options chain, and decided to focus on the TGT Weekly $75-76.50 Calls for a fresh options idea. It was an immediate success, with TGT trading up enough to produce some really nice single-session swings.

$75 Calls – Range: 1.42-2.42 – Max Gain: 70%
$75.50 Calls – Range: 1.03-1.92 – Max Gain: 86%
$76 Calls – Range: .85-1.64 – Max Gain: 93%
$76.50 Calls – Range: .80-1.31 – Max Gain: 64%


Dean Foods Co. DF

We also want to put DF on our watchscreens as a bottom-watch play. The stock got absolutely crushed as a result of missed earnings and revenue estimates in its Q4 report, along with a  downgrade by Credit Suisse.

These events have driven DF into heavily oversold territory, registering a new 52-week low. The stock also has a history of relatively volatile swings, so we’re going to watch closely for the beginnings of a bottom bounce in sessions ahead. It may have further to fall, but we’ll be looking for that rebound.


Extended Watchlist:
AIPT, AKER, DDS, MNK, TTS, JCP, TTPH,

Blue Horseshoe Stocks: Bottom-Bouncers & More


North Atlantic Drilling Ltd. NADL

We’ve got an array of potential bottom-bounce plays to go over this morning, the first of which is NADL. This stock has been getting beaten down incrementally since reaching a high of 4.80 in December. It’s been one selloff after another since then, culminating in a low of .65 during yesterday’s session.

We’re seeing a moderate gap-up this morning, and want to put NADL on our watchlist moving forward on the chance that a multi-day rebound is on the way.

__________

Catalyst BioSciences, Inc. CBIO

Next up on our bottom-bounce watchlist is CBIO, which is also gapping up off of a bottom in the premarket this morning with the help of a key press release, of which we’ll include a snippet below.

The stock recently made a massive run to the $18, so the potential for another major move is certainly present.

SOUTH SAN FRANCISCO, Calif., April 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc., (Nasdaq:CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a key milestone under its collaboration with ISU Abxis to advance the Factor IX program towards its first human clinical trial. Completion of the CB 2679d/ISU304 toxicology studies supported the recent Investigational New Drug (IND) approval by the Korean Ministry of Food and Drug Safety (MFDS) and triggered a milestone payment to Catalyst. (>>View Full PR)
__________

Sunshine Heart, Inc. SSH

We tagged SSH as a bottom play a week ago today on the 4th, and subsequently tracked it over a pretty nice run last week as it traded up from 1.67 and hit 2.25 (+35%). It pulled back to the low 1.70′s yesterday and appears to be gearing up for another possible move.

Just two months ago the stock was trading at more than $5/share, so we wanted to add a little reminder this morning that SSH could be line for an extended recovery that we’ll want to look out for in the day and weeks ahead.


Galectin Therapeutics, Inc. GALT

We were just mentioning yesterday morning the excellent move from GALT we had witnessed between first bringing it up in January and the present. The run, originating at a low of .935 had already reached just beyond the 200% level, and after a very nice intraday performance, our observed range was extended even further.

Trading up from a morning low to 2.75, the stock traded up 34% to reach 3.68. That pushed the overall percentage gain we’ve witnessed in GALT for 2017 to a highly respectable 294%


Extended Watchlist:
AMLH, SALE, GLBS, AKER, STAF